<DOC>
	<DOCNO>NCT02709109</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy treatment VX-371 saline compare saline alone subject cystic fibrosis ( CF ) ≥12 year age , homozygous F508del-CFTR mutation , treat Orkambi</brief_summary>
	<brief_title>A Study Evaluate Safety Efficacy VX-371 Subjects With Cystic Fibrosis Who Are Homozygous F508del-CFTR Mutation</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<criteria>Willing able use delivery device direct study manual . Confirmed diagnosis CF , define sweat chloride value ≥60 mmol/L quantitative pilocarpine iontophoresis . Homozygous F508del CFTR mutation . If CFTR screen genotype result receive randomization , previous CFTR genotype lab report may use establish eligibility . Percent predict FEV1 ≥40 &lt; 90 percentage point adjust age , sex , height accord Global Lung Initiative ( GLI ) Screening Visit . Willing discontinue physicianprescribed saline use . Female subject childbearing potential negative serum pregnancy test Screening Visit . History comorbidity , opinion investigator , might confound result study pose additional risk administer study drug subject . Any clinically significant laboratory abnormality Screening Visit would interfere study assessment pose undue risk subject . An acute upper low respiratory infection , pulmonary exacerbation , change therapy ( include antibiotic ) pulmonary disease within 28 day Day 1 ( first dose study drug ) . A 12 lead ECG demonstrate QTcF &gt; 450 msec Screening Visit . History solid organ hematological transplantation . Used diuretic reninangiotensin aldosterone system antihypertensive drug 28 day prior Screening anticipate need medication study . Ongoing prior participation investigational drug study within 30 day Screening Visit . Inability withhold shortacting , longacting , oncedaily , longacting bronchodilator use 4 , 12 , 24 hour prior clinic visit , respectively . History significant intolerance inhale saline , intolerance single dose saline Screening Known hypersensitivity history intolerance Orkambi . Pregnant nursing female . Subjects participate Parion Sciences Study NCT02343445 .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>